Douglas Gause

937 total citations
20 papers, 729 citations indexed

About

Douglas Gause is a scholar working on Pharmacology, Endocrinology, Diabetes and Metabolism and Psychiatry and Mental health. According to data from OpenAlex, Douglas Gause has authored 20 papers receiving a total of 729 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pharmacology, 4 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Psychiatry and Mental health. Recurrent topics in Douglas Gause's work include Diabetes, Cardiovascular Risks, and Lipoproteins (4 papers), Nail Diseases and Treatments (3 papers) and Lipoproteins and Cardiovascular Health (3 papers). Douglas Gause is often cited by papers focused on Diabetes, Cardiovascular Risks, and Lipoproteins (4 papers), Nail Diseases and Treatments (3 papers) and Lipoproteins and Cardiovascular Health (3 papers). Douglas Gause collaborates with scholars based in United States, Switzerland and Spain. Douglas Gause's co-authors include Stephen Arcona, Cristina Varas, Leslie Leahy, Ross J. Baldessarini, John Hennen, Jennifer Sung, Frederick L. Brancati, Sharon Saydah, Montserrat Miret and Christie M. Ballantyne and has published in prestigious journals such as Circulation, Diabetes Care and The American Journal of Cardiology.

In The Last Decade

Douglas Gause

18 papers receiving 693 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Douglas Gause United States 11 250 201 121 113 74 20 729
Charlotte Hindsberger Denmark 14 37 0.1× 480 2.4× 69 0.6× 241 2.1× 248 3.4× 23 1.0k
A. A. H. Lawson United Kingdom 16 75 0.3× 39 0.2× 41 0.3× 105 0.9× 61 0.8× 41 713
Robert P. Kauffman United States 15 44 0.2× 238 1.2× 141 1.2× 37 0.3× 50 0.7× 48 1.2k
Anat Jaffe Israel 12 58 0.2× 486 2.4× 41 0.3× 30 0.3× 92 1.2× 25 712
Sandra N. Slagter Netherlands 13 25 0.1× 337 1.7× 106 0.9× 19 0.2× 47 0.6× 17 771
D Schröder-Bernhardi Germany 9 59 0.2× 103 0.5× 45 0.4× 24 0.2× 36 0.5× 19 442
Samantha K. Hutchison Australia 14 29 0.1× 269 1.3× 43 0.4× 66 0.6× 28 0.4× 16 1.3k
Giuseppe Fatati Italy 13 32 0.1× 84 0.4× 35 0.3× 46 0.4× 70 0.9× 41 582
Rafael García‐Robles Spain 17 35 0.1× 381 1.9× 62 0.5× 51 0.5× 191 2.6× 43 1.1k
Ivar Aursnes Norway 15 68 0.3× 60 0.3× 48 0.4× 66 0.6× 62 0.8× 56 692

Countries citing papers authored by Douglas Gause

Since Specialization
Citations

This map shows the geographic impact of Douglas Gause's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Gause with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Gause more than expected).

Fields of papers citing papers by Douglas Gause

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Gause. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Gause. The network helps show where Douglas Gause may publish in the future.

Co-authorship network of co-authors of Douglas Gause

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Gause. A scholar is included among the top collaborators of Douglas Gause based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Gause. Douglas Gause is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Frech‐Tamas, Feride, et al.. (2009). Abstract 1581: Patient Compliance With Single Pill, Dual and Triple Antihypertensive Combinations. Circulation. 120(14). e2400003–e2400003. 1 indexed citations
2.
Baldessarini, Ross J., et al.. (2007). Patterns of Psychotropic Drug Prescription for U.S. Patients With Diagnoses of Bipolar Disorders. Psychiatric Services. 58(1). 85–91. 216 indexed citations
3.
Suh, Dong‐Churl, et al.. (2007). Economic Burden of Atopic Manifestations in Patients With Atopic Dermatitis - Analysis of Administrative Claims. Journal of Managed Care Pharmacy. 13(9). 778–789. 39 indexed citations
4.
Delea, Thomas E., Manjusha Gokhale, Charles Makin, et al.. (2007). Administrative Claims Analysis of Utilization and Costs of Care in Health Plan Members With Atopic Dermatitis Who Had Prior Use of a Topical Corticosteroid and Who Initiate Therapy With Pimecrolimus or Tacrolimus. Journal of Managed Care Pharmacy. 13(4). 349–359. 11 indexed citations
5.
Jacobson, Terry A., Christopher Case, Seth Roberts, et al.. (2004). Characteristics of US adults with the metabolic syndrome and therapeutic implications. Diabetes Obesity and Metabolism. 6(5). 353–362. 34 indexed citations
6.
Beusterien, Kathleen, Simu K. Thomas, Douglas Gause, et al.. (2004). Impact of Rivastigmine Use on the Risk of Nursing Home Placement in a US Sample. CNS Drugs. 18(15). 1143–1148. 28 indexed citations
7.
Cerulli, Antonietta, et al.. (2004). PUK4 PATIENT PERCEPTION OF OAB DRUG THERAPY SUCCESS IS ASSOCIATED WITH LESS HEALTHCARE RESOURCE USE. Value in Health. 7(6). 798–799. 1 indexed citations
8.
Case, Christopher, Terry A. Jacobson, Susan B. Roberts, et al.. (2003). Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol. The American Journal of Cardiology. 91(9). 1134–1136. 5 indexed citations
9.
Stier, David M., Douglas Gause, Warren S. Joseph, et al.. (2001). Patient Satisfaction with Oral versus Nonoral Therapeutic Approaches in Onychomycosis. Journal of the American Podiatric Medical Association. 91(10). 521–527. 5 indexed citations
10.
Gause, Douglas, et al.. (2001). PND9: IMPACT OF RIVASTIGMINE ON ANTIPSYCHOTIC UTILIZATION AND COST IN ALZHEIMER'S DISEASE. Value in Health. 4(6). 520–521. 1 indexed citations
11.
Saydah, Sharon, Montserrat Miret, Jennifer Sung, et al.. (2001). Postchallenge Hyperglycemia and Mortality in a National Sample of U.S. Adults. Diabetes Care. 24(8). 1397–1402. 176 indexed citations
12.
Jacobson, Terry A., et al.. (2000). Impact of Evidence-Based "Clinical Judgment" on the Number of American Adults Requiring Lipid-Lowering Therapy Based on Updated NHANES III Data. Archives of Internal Medicine. 160(9). 1361–1361. 63 indexed citations
13.
Frost, Floyd J., Judith S. Hurley, Hans Petersen, Marc J. Gunter, & Douglas Gause. (2000). A Comparison of Two Methods for Estimating the Health Care Costs of Epilepsy. Epilepsia. 41(8). 1020–1026. 32 indexed citations
14.
Gause, Douglas, et al.. (2000). Cost savings from decreased utilization of antipsychotic drugs associated with rivastigmine use in long term care facilities. Neurobiology of Aging. 21. 167–167. 1 indexed citations
15.
Lubeck, Deborah P., et al.. (1999). A health-related quality of life measure for use in patients with onychomycosis: a validation study. Quality of Life Research. 8(1-2). 121–129. 40 indexed citations
16.
Gause, Douglas, et al.. (1997). Onychomycosis. Baseline results of an observational study. Journal of the American Podiatric Medical Association. 87(11). 512–519. 46 indexed citations
17.
Lanza, Lee L., et al.. (1995). Incidence of symptomatic liver function abnormalities in a cohort of NSAID users. Pharmacoepidemiology and Drug Safety. 4(4). 231–237. 19 indexed citations
18.
Lavenhar, Marvin A., et al.. (1981). Problems in retrospectively evaluating a large-scale health inter vention program. Journal of Community Health. 6(3). 164–180. 4 indexed citations
19.
Fine, Burton P., et al.. (1979). The effects of body burdens of lead on the growing rat kidney. Environmental Research. 19(2). 215–220. 5 indexed citations
20.
Gause, Douglas, et al.. (1977). Reduction in lead levels among children in Newark.. PubMed. 74(11). 958–60. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charlotte Hindsberger Breakdown of academic impact, for papers by A. A. H. Lawson Breakdown of academic impact, for papers by Robert P. Kauffman Breakdown of academic impact, for papers by Anat Jaffe Breakdown of academic impact, for papers by Sandra N. Slagter Breakdown of academic impact, for papers by D Schröder-Bernhardi Breakdown of academic impact, for papers by Samantha K. Hutchison Breakdown of academic impact, for papers by Giuseppe Fatati Breakdown of academic impact, for papers by Rafael García‐Robles Breakdown of academic impact, for papers by Ivar Aursnes
Rankless by CCL
2026